Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
3.100
-0.080 (-2.52%)
At close: Nov 22, 2024, 4:00 PM
3.080
-0.020 (-0.65%)
After-hours: Nov 22, 2024, 5:46 PM EST
Pasithea Therapeutics Employees
Pasithea Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 7 or -46.67% compared to the previous year.
Employees
8
Change (1Y)
-7
Growth (1Y)
-46.67%
Revenue / Employee
n/a
Profits / Employee
-$1,971,885
Market Cap
3.93M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | -7 | -46.67% |
Dec 31, 2022 | 15 | 10 | 200.00% |
Dec 31, 2021 | 5 | 2 | 66.67% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
China Pharma Holdings | 231 |
Biofrontera | 85 |
Genetic Technologies | 55 |
Genprex | 26 |
Hepion Pharmaceuticals | 22 |
Windtree Therapeutics | 20 |
Sonoma Pharmaceuticals | 10 |
Artelo Biosciences | 6 |
KTTA News
- 2 days ago - Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Why Is Pasithea Therapeutics Stock Surging On Thursday? - Benzinga
- 2 months ago - Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting - GlobeNewsWire